Loading
Knight Therapeutics Inc. Stock: price and insider trades · Canada
CA·Mcap CA$1.1B
Knight Therapeutics Inc.: what insiders have been doing
Knight Therapeutics Inc. is a listed company. Its insiders report their share dealings to SEDI. In the past year (18 October 2025 to 18 October 2026), 47 filings came from 10 insiders.
No insider bought on the market over the period, while 1 insider filed 5 sales totalling €257k. Groleau, Melanie filed the largest sale, €169k, on 10 June 2026, which represents 0.028% of the company's market value.
Typically, a trade is published a median of 3 days after it takes place. This delay matters because a trade only becomes useful information once it is public. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
With 47 filings in twelve months, the company is more active than the median of 12 filings across the 2,120 companies we follow on the same exchange. Since 2026, the database holds no purchases and 5 sales by insiders of the company.
Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Insider Decl.
47
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€256,637
5 ops. · all time
Who traded when
BuySaleMelanie Groleau6 sales
Analyst consensus: bullish or bearish?
Analysts rate Knight Therapeutics Inc. Strong Buy (bullish), based on 7 analysts. Average price target: CA$11.19.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,941 of 24,148 companies
41.2
score / 100
Value37
Quality45
FCF yld3.3%
Earn yld-0.5%
EV/EBITDA18.9x
ROE1.9%
Gross mgn44%
Net mgn-1.2%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$10.83
Analyst consensus
7 analystsStrong buy
CA$10.80Target CA$11.19(+3%)CA$12.00
Income statement
RevenueCA$450.1M
Gross profitCA$200.2M44% margin
EBITDACA$60.3M13% margin
Net income-CA$5.4M2.7% margin
Valuation
PER (trailing)72.2x
PER (forward)41.7x
P/Book1.3x
Beta-0.01
Balance sheet & cash
Market capCA$1.1B
Total debtCA$77.9M
Free Cash FlowCA$35.3M
Debt / Equity4%
Profitability & ownership
ROE1.9%
ROA1.3%
% insiders46.0%
% institutions19.0%
Last declaration on 18 September 2026
Declarations47 total
186 shares@ CA$5.630.0001% mcap6.3% of flowCommon SharesTSXSEDI:4778910
722 shares@ CA$9.870.0007% mcap43.0% of flowCommon SharesTSXSEDI:4778909
600 shares@ CA$5.630.0003% mcap8.3% of flowCommon SharesTSXSEDI:4778908
1,581 shares@ CA$9.870.0016% mcap38.4% of flowCommon SharesTSXSEDI:4778907
292 shares@ CA$5.630.0002% mcap8.8% of flowCommon SharesTSXSEDI:4778906
714 shares@ CA$9.870.0007% mcap37.7% of flowCommon SharesTSXSEDI:4778905
223 shares@ CA$5.630.0001% mcap8.3% of flowCommon SharesTSXSEDI:4778904
587 shares@ CA$9.870.0006% mcap38.4% of flowCommon SharesTSXSEDI:4778903
274 shares@ CA$5.630.0002% mcap0.4% of flowCommon SharesTSXSEDI:4778902
686 shares@ CA$9.870.0007% mcap1.6% of flowCommon SharesTSXSEDI:4778901
506 shares@ CA$5.630.0003% mcap14.7% of flowCommon SharesTSXSEDI:4778900
633 shares@ CA$9.870.0006% mcap32.3% of flowCommon SharesTSXSEDI:4778899
8,066 shares@ CA$7.750.0063% mcap14.6% of flowCommon SharesTSXSEDI:4752576
45,054 shares@ CA$7.750.035% mcap81.6% of flowOptionsTSXSEDI:4752573
8,035 shares@ CA$9.850.0079% mcap17.2% of flowRestricted Share UnitTSXSEDI:4749579
Restricted Share UnitTSXSEDI:4749575
16,069 shares@ CA$9.850.016% mcap34.5% of flowPerformance stock UnitTSXSEDI:4749573
Performance stock UnitTSXSEDI:4749566
22,540 shares@ CA$9.850.022% mcap48.3% of flowOptionsTSXSEDI:4749564
OptionsTSXSEDI:4749554
200 shares@ CA$5.220.0001% mcap6.2% of flowCommon SharesTSXSEDI:4736915
794 shares@ CA$9.360.0008% mcap44.4% of flowCommon SharesTSXSEDI:4736914
140 shares@ CA$5.220.0001% mcap100.0% of flowCommon SharesTSXSEDI:4736912
720 shares@ CA$5.220.0004% mcap9.2% of flowCommon SharesTSXSEDI:4736911
1,934 shares@ CA$9.360.0019% mcap44.1% of flowCommon SharesTSXSEDI:4736910
25 of 47 declarations
About Knight Therapeutics Inc.
Knight Therapeutics Inc. is a Canadian pharmaceutical company focused on acquiring and developing drugs for the Canadian and international markets. It is listed on the Toronto Stock Exchange under the symbol KNT.
